PRINCETON, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Reported revenues were $434.9 million, representing a decrease of 1.7% on a reported basis and 2.5% on an organic basis compared to the fourth quarter of 2024. GAAP earnings per diluted share were $(0.02), compared to $0.25 in the fourth quarter of 2024.Adjusted earnings per diluted share ...

The Marlborough, Massachusetts-based Boston Scientific Corporation (BSX) designs and commercializes medical devices that power minimally invasive procedures across cardiovascular, urology, neurology, oncology, and gastrointestinal care. With a market capitalization of about $111.5 billion, the company stands in the “large-cap” territory, a bracket reserved for businesses valued above $10 billion. This scale provides reach, capital flexibility, and a global sales infrastructure that supports hospitals and ...

截至午间收盘，科创成长指数上涨1.5%，科创200指数上涨1.0%，科创100指数上涨0.9%，科创综指上涨0.6%，科创50指数上涨 0.1%。 | 科创50ETF易方达 低费率 | | | 588080 | | --- | --- | --- | --- | | 跟踪上证科创板50成份指数 | | | | | 该指数由科创板中市值大、流动性 | 截至午间收盘 | 该指数 | 该指数自2020年 | | 好的50只股票组成,"硬科技"龙 | 该指数涨跌 | 滚动市智率 | 发布以来估值分位 | | 头特征显著,半导体占比超65%, | | | | | 与医疗器械、软件开发、光伏设备 行业合计占比近80% | 0. 1% | 167. 3倍 | 95. 4% | | 【保要率 科创100ETF易方达 | | | 588210 | | 跟踪上证科创板100指数 | | | | | 该指数由科创板中市值中等且流动 性较好的100只股票组成,聚焦中 | 截至午间收盘 该指数涨跌 | 该指数 滚动市盈率 | 该指数 | | 小科创企业,电子、电力设备、医 | | | | | 药生物、计算机行业合计占比超 | | | ...

LeMaitre Vascular (NasdaqGM:LMAT) Q4 2025 Earnings call February 25, 2026 05:00 PM ET Company ParticipantsDanny Stauder - Director of Equity ResearchDave Roberts - PresidentDorian LeBlanc - CFOGeorge LeMaitre - CEORick Wise - Managing DirectorConference Call ParticipantsBrett Fishbin - VP and Senior Equity Research AnalystJim Sidoti - AnalystKyle Bauser - Managing Director and Senior Research AnalystMichael Petusky - Managing Director and Senior Investment AnalystMichael Sarcone - Equity AnalystNone - Analy ...

Carlsmed (NasdaqGS:CARL) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsCaroline Corner - Investor RelationsFelipe Lamar - Senior Equity Research AssociateLeo Greenstein - CFOMichael Cordonnier - CEO and ChairmanTravis Steed - Managing Director in Equity ResearchConference Call ParticipantsJenny Rabinowitz - Global Investment Research AnalystRyan Zimmerman - Managing Director and Senior Equity Research AnalystNone - AnalystOperatorLadies and gentlemen, thank you for standing by, and ...

Carlsmed (NasdaqGS:CARL) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsCaroline Corner - Investor RelationsFelipe Lamar - Senior Equity Research AssociateLeo Greenstein - CFOMichael Cordonnier - CEO and ChairmanTravis Steed - Managing Director in Equity ResearchConference Call ParticipantsJenny Rabinowitz - Global Investment Research AnalystRyan Zimmerman - Managing Director and Senior Equity Research AnalystNone - AnalystOperatorLadies and gentlemen, thank you for standing by, and ...

For the quarter ended December 2025, Penumbra (PEN) reported revenue of $385.39 million, up 22.1% over the same period last year. EPS came in at $1.18, compared to $0.97 in the year-ago quarter.The reported revenue represents a surprise of +6.74% over the Zacks Consensus Estimate of $361.04 million. With the consensus EPS estimate being $1.12, the EPS surprise was +5.36%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ex ...

MiMedx Group (NasdaqCM:MDXG) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker7Good afternoon, and thank you for standing by. Welcome to the MiMedx fourth quarter and full year 2025 operating and financial results conference call. At this time, all participants are in listen-only mode. The question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Matt Notarianni, Head of Investor ...

Carlsmed (NasdaqGS:CARL) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker5Ladies and gentlemen, thank you for standing by, and welcome to the Carlsmed fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. I would now like to turn the conference over to your first speaker today, Caroline Corner, Investor Relations. Please go ahead, Caroline.Speaker1Thank yo ...

ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its pending acquisition by Alcon Research, LLC (“Alcon”). The Company and Alcon continue to cooperate with the U.S. Federal Trade Commission (the “FTC”) staff in connection with its Request for Additional Information and Documentary Material (the “Seco ...